Goldman Sachs
EWTX icon

Goldman Sachs’s Edgewise Therapeutics EWTX Stock Holding History

Goldman Sachs’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4M Sell
599,469
-30,351
-5% -$1.05M ﹤0.01% 2444
2026
Q1 		$19.8M Sell
629,820
-88,552
-12% -$2.55M ﹤0.01% 2441
2025
Q4 		$17.8M Buy
718,372
+190,545
+36% +$3.82M ﹤0.01% 2503
2025
Q3 		$8.56M Sell
527,827
-103,916
-16% -$1.47M ﹤0.01% 3116
2025
Q2 		$8.28M Buy
631,743
+265,099
+72% +$3.82M ﹤0.01% 2930
2025
Q1 		$8.07M Buy
366,644
+19,753
+6% +$518K ﹤0.01% 2899
2024
Q4 		$9.26M Sell
346,891
-135,334
-28% -$4.31M ﹤0.01% 2876
2024
Q3 		$12.9M Sell
482,225
-1,140,516
-70% -$22.7M ﹤0.01% 2463
2024
Q2 		$29.2M Sell
1,622,741
-125,103
-7% -$2.18M ﹤0.01% 1552
2024
Q1 		$31.9M Buy
1,747,844
+865,948
+98% +$13.8M 0.01% 1478
2023
Q4 		$9.65M Sell
881,896
-65,898
-7% -$463K ﹤0.01% 2572
2023
Q3 		$5.43M Sell
947,794
-806,055
-46% -$5.48M ﹤0.01% 2915
2023
Q2 		$13.6M Buy
1,753,849
+999,710
+133% +$8.43M ﹤0.01% 2173
2023
Q1 		$5.03M Sell
754,139
-310,982
-29% -$2.88M ﹤0.01% 3062
2022
Q4 		$9.52M Buy
1,065,121
+1,002,520
+1,601% +$9.4M ﹤0.01% 2640
2022
Q3 		$616K Sell
62,601
-83,214
-57% -$841K ﹤0.01% 4833
2022
Q2 		$1.16M Buy
145,815
+13,649
+10% +$103K ﹤0.01% 4500
2022
Q1 		$1.28M Buy
132,166
+91,654
+226% +$1.18M ﹤0.01% 4628
2021
Q4 		$619K Buy
+40,512
New +$729K ﹤0.01% 5225
2021
Q2 		– Sell
-65,263
Closed -$2.12M – 6280
2021
Q1 		$2.12M Buy
+65,263
New +$2.12M ﹤0.01% 3917

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's EWTX Position: Q2 2026 in Review

Goldman Sachs reduced its Edgewise Therapeutics (EWTX) stake by 4.8% in Q2 2026, selling an estimated $1.05M and leaving 599,469 shares worth $24.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

Goldman Sachs first reported a position in EWTX in Q1 2021 and has held it in 20 quarters since. The position peaked at $31.9M in Q1 2024. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Goldman Sachs held 599,469 shares of Edgewise Therapeutics worth $24.4M as of Q2 2026.
  • Goldman Sachs sold 30,351 Edgewise Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Edgewise Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2444 holding.
  • Goldman Sachs first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Goldman Sachs's Edgewise Therapeutics position peaked at $31.9M in Q1 2024.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.